This white paper includes contributions from guest author Masahisa Jinushi, head of medical affairs, Gilead Sciences.
The pharmaceutical industry in Japan stands at a crossroads due to rising costs, fragmented patient care and regulatory pressures. To ensure Japan’s healthcare industry becomes a critical driver of future economic growth, pharma companies must proactively champion improvements in efficiency and quality of care. This will help the sector become a key player, influencing both government policy and society at large.
Medical affairs teams can lead this charge by establishing a rigorous framework for evaluating the real-world impact and tangible outcomes of teams’ current activities. By centering assessments on outcomes, medical affairs can ensure resources and efforts are aligned with the most critical needs, laying a solid foundation for future initiatives.
To discuss this opportunity and more, ZS facilitated a roundtable discussion in Tokyo with nine heads of medical affairs from leading pharmaceutical companies in Japan.
These medical affairs leaders highlighted five key steps pharma organizations in Japan can take to elevate their role in the healthcare ecosystem:
- Adopt outcome-oriented metrics to measure tangible medical affairs impact
- Elevate patient and public voice to contribute to the healthcare ecosystem and shape clinical care pathways
- Leverage advanced real-world data infrastructures to generate evidence and expand strategic use cases
- Harness AI to optimize medical affairs’ efficiency and impact
- Cultivate talent and foster a future-ready team culture
Download the white paper to learn how medical affairs teams in Japan can affirm their emergence as pharma companies’ “third pillar.” We share their role in driving innovation, fostering trust and, above all, improving patient outcomes across the healthcare ecosystem.
Add insights to your inbox
We’ll send you content you’ll want to read – and put to use.
